+

WO1995023970A1 - Essai destine au diagnostic de la schizophrenie - Google Patents

Essai destine au diagnostic de la schizophrenie Download PDF

Info

Publication number
WO1995023970A1
WO1995023970A1 PCT/US1995/002426 US9502426W WO9523970A1 WO 1995023970 A1 WO1995023970 A1 WO 1995023970A1 US 9502426 W US9502426 W US 9502426W WO 9523970 A1 WO9523970 A1 WO 9523970A1
Authority
WO
WIPO (PCT)
Prior art keywords
platelet
antibody
paa
sample
assay according
Prior art date
Application number
PCT/US1995/002426
Other languages
English (en)
Inventor
Meir Shinitzky
Michael Deckmann
Original Assignee
Yeda Research And Development Co. Ltd.
Rycus, Avigail
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL10878994A external-priority patent/IL108789A/en
Priority claimed from IL11014294A external-priority patent/IL110142A0/xx
Application filed by Yeda Research And Development Co. Ltd., Rycus, Avigail filed Critical Yeda Research And Development Co. Ltd.
Priority to EP95912625A priority Critical patent/EP0748447A4/fr
Priority to JP7522960A priority patent/JPH09510012A/ja
Priority to BR9507125A priority patent/BR9507125A/pt
Priority to AU19716/95A priority patent/AU695043B2/en
Publication of WO1995023970A1 publication Critical patent/WO1995023970A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells

Definitions

  • the present invention relates to an assay for the diagnosis of schizophrenia.
  • the schizophrenic disorders as defined by DSM-III
  • Schizophrenia occurs worldwide. Although it is one of the most severe and prevalent mental disorders of well documented symptomatology and has been extensively investigated over the past decades, the etiology of this disease is still an enigma.
  • Alzheimer-type and multi-infarct dementia both treated with neuroleptics and untreated
  • normal control subjects was determined by the use of an enzyme-linked immunoassay based on color development after reaction with anti-human immunoglobulin (anti-human IgA, IgE, IgG and IgM antibodies) bound to horseradish peroxidase.
  • anti-human immunoglobulin anti-human IgA, IgE, IgG and IgM antibodies
  • PAA isolated from schizophrenic patients were contacted with proteins isolated from platelets (hereinafter "platelet antigens") and all cases developed a similar binding pattern. It was surprisingly found that the PAA from schizophrenic patients did not recognize and bind to well- known antigenic proteins from platelets involved in ITP, but recognized and bound to unknown platelet antigens which, on the other hand, were not recognized by the PAA from demented patients.
  • the present invention provides an assay for the diagnosis of schizophrenia in an individual, comprising the following steps:
  • a sample from said individual being a blood sample, a platelet-containing fraction thereof, or a fraction containing platelet-associated antibodies (PAA) shed from the platelets;
  • PPA platelet-associated antibodies
  • the sample of the individual to be tested may be a blood sample, e.g. serum, a platelet-containing fraction thereof or a PAA-containing fraction shed from the platelets.
  • the sample is platelet-rich plasma (PRP) obtained by known methods, e-g-*, treatment of blood with an anticoagulant, e.g. heparin or sodium citrate solution, and centrifugation.
  • PRP platelet-rich plasma
  • the sample is a fraction containing PAA, obtained by centrifugation of PRP, incubation of the pelleted platelets with glycine-HCl buffer, pH 2.5-3.0 at room temperature and centrifugation, thus obtaining a PAA- containing supernatant.
  • the platelet antigens are obtained e.g. by disintegration of platelets derived from PRP and separated according to their molecular weights by polyacrylamide gel electrophoresis (PAGE) and transfer to a solid support, e.g., nitrocellulose.
  • PAGE polyacrylamide gel electrophoresis
  • the antibody detection systems to detect PAA levels comprises anti-human immunoglobulin (anti-hlg) antibody, or a fragment thereof, linked to a marker.
  • a marker may, for example, be a radioactive group, a fluorescent group, an enzyme that can catalyze a reaction yielding a detectable product such as, for example, horseradish peroxidase (HRP) and alkaline phosphatase, a biotin group that can be detected by avidin, etc.
  • HRP horseradish peroxidase
  • alkaline phosphatase a biotin group that can be detected by avidin
  • the antibody is rabbit anti-human IgG (anti-hlgG) covalently linked to HRP and ortho-phenyl-enediamine is the reagent used to detect bound HRP.
  • a fragment of IgG is used which is Fc-depleted, such as an Fab or an F(ab ) 2 fragment or a part thereof which contains the fragment's binding domain, or a single-chain antibody, or the like.
  • the degree of binding of the antibodies to PAA can be determined by the use of a second antibody directed against said single domain antibody, which second antibody is bound to a marker as above.
  • a solid support having immobilized thereon a PAA target antigen(s) specific for schizophrenia, i.e., the antigen(s) to which the PAA of schizophrenic patients are directed, is used.
  • the PAA target antigen( ⁇ ) specific for schizophrenia will be isolated from the antigenic proteins recognized by the PAA from schizophrenic patients, purified and characterized.
  • the platelets are contacted with the support and following an incubation period, the immobilized platelets are reacted with the anti-hlg antibodies, which are preferably labelled and the number of bound PAA can thus be determined.
  • the platelets are first treated to shed their PAA, the PAA-containing fraction is then reacted with the support and following incubation and washing, the supports are reacted with the anti-hlg antibodies which are preferably labelled, and the number of bound PAA is thus determined.
  • the present invention also provides a kit useful in the above assay.
  • the kit of the invention comprises an anti-hlg antibody or a fragment thereof and a support comprising a sole antigen or a plurality of platelet antigens reactive with the PAA immobilized onto the support.
  • the antibodies in the kit are conjugated to a detectable marker.
  • the kit comprises also a second type of antibodies directed against said single domain antibodies, which second type of antibodies are in turn conjugated to a detectable marker.
  • the antibodies are immobilized onto a support and the kit comprises such a support.
  • the kit according to all above embodiments may also comprise the various reagents required for carrying out the assay.
  • Figs. 1A-B show the pattern of binding by Western blot of PAA obtained from 10 normal control subjects (A) and 8 schizophrenic patients (B) to platelet antigens in a nitrocellulose support, separated by 10% acrylamide gel, as determined by HRP-labelled rabbit anti-human IgG.
  • Figs. 2A-C show the pattern of binding by Western blot of PAA from 4 schizophrenic patients (A) , 4 normal control subjects (B) and 4 demented patients (C) to platelet antigens in a nitrocellulose support, separated by 10% acrylamide gel, as determined by HRP-labelled rabbit anti-human IgG.
  • Fig. 3 shows the pattern of binding by Western blot of PAA from 10 schizophrenic patients (lanes 1-10) to platelet antigens on a nitrocellulose support, separated by a 7,5-15% acrylamide gradient gel, as determined by HRP-labelled rabbit anti-human IgG.
  • PAA levels were determined either with rabbit anti-human IgG antibodies linked to HRP (as in Shinitzky et al.., 1991) or with a Fab fragment of this antibody. Enzyme-linked immunoassay (ELI) based on a color development after binding of the antibody or Fab fragment thereof, was used.
  • ELI Enzyme-linked immunoassay
  • activated plastic beads (Immunotip, U.S.A. Scientific Plastics) were coupled with papain as follows: 1 mg papain (Worthington, U.S.A.) was mixed in 1 ml of 0.2M sodium cyanoborohydride (Fluka, U.S.A.) and was incubated with a single plastic bead for 5-10 minutes, and then washed extensively with phosphate-buffered saline (PBS) .
  • PBS phosphate-buffered saline
  • Horseradish peroxidase-conjugated rabbit anti- human IgG (BioMakor, Israel; 740 ⁇ g in 40 ⁇ l) was incubated with gentle shaking with the papain-conjugated bead for 5 hours at 37°C and then passed through a protein A column (Pierce) .
  • the platelet suspension was incubated with freshly prepared substrate reagent (19.8 ml PBS - 0.2 ml methanol containing 2 mg ortho- phenylenediamine ⁇ 3 ⁇ l H 2 0 2 30%) for 1 hr at 37°C.
  • substrate reagent (19.8 ml PBS - 0.2 ml methanol containing 2 mg ortho- phenylenediamine ⁇ 3 ⁇ l H 2 0 2 30%
  • the reaction was terminated by adding 0.1 ml of 6N sulfuric acid. After centrifugation, the O.D. was read at 480 nm. After background substraction, the O.D. was calculated for 10 8 platelets per ml (Shinitzky et al., 1991).
  • Platelets were derived from PRP by 3 washings with PBS and separated by PAGE according to their molecular weights as described (Laemmli U.K., Nature, 227. 680 (1970)). Depending on the molecular weight of interest, 5%, 10% or 12.5% acrylamide concentrations were used. Alternatively, a 7,5-15% acrylamide gradient gel was used, leading to a better resolution than homogeneous acrylamide concentration.
  • Platelet proteins from control subjects were separated by 10% PAGE and blotted onto nitrocellulose as described in (v) above. All incubation steps were performed at room temperature and under constant shaking (Bellco Rocking Table, speed setting 4) in BioRad Incubation Trays.
  • the sample strips and positive control strip (dotted with 0.002 ml human serum) were blocked with 1 ml blocking buffer (5% milk powder dissolved in incubation buffer [60 mM citric acid, 90 mM Na 2 HP0 4 , 200 mM NaCl, pH 7.7] filtered before use) for 30 min. The blocking buffer was then carefully removed (with a Pasteur pipette) and the strips were supplemented with 1 ml incubation buffer.
  • PAA 0.2 ml or serum (0.1 ml) was then added to the strips as a sample and incubated for 14 hours. After the incubation, the strips were washed 3 times with 1 ml incubation buffer for 15 min. and one time with 1 ml peroxidase buffer (200 mM Tris, 150 mM KC1, 0.3% Triton X-100, 10 mM phenol, 2 mM CaCl 2 , filtered before use) for 15 min. The strips were incubated with rabbit anti-human IgG covalently linked to peroxidase (1:1000 diluted) in 1 ml peroxidase buffer for 2 hours.
  • 1 ml peroxidase buffer 200 mM Tris, 150 mM KC1, 0.3% Triton X-100, 10 mM phenol, 2 mM CaCl 2 , filtered before use
  • Fig. IA PAA from 10 blood donors (Fig. IA) and from 8 chronic schizophrenic patients (Fig. IB) were incubated with normal human platelet proteins, separated by gel electrophoresis and blotted onto nitrocellulose as described above. Visual detection of bound PAA was carried out as described above. The results are shown in Fig. 1 , in which the following molecular weight markers (BioRad) were used: lysozyme - 14.4 kD; trypsin inhibitor - 21.5 kD;; carbonic anhydrase - 31 kD; ovalbumin - 45 kD; serum albumin - 66.2 kD and phosphorylase B - 97.4 kD. No bands were observed in any of the 10 examples of PAA from normal donors (Fig. IA) , while in all 8 examples of PAA from chronic schizophrenic patients a series of bands was detected (Fig. IB) .
  • BioRad molecular weight markers
  • Idiopathic Thrombocytopenia Purpura are Proteins I b ( -unit, 128-141 kD; 3-unit, 22 kD) , II b ( ⁇ -unit, 132 kD; 3-unit, 23 kD) and III a (95 kD) (Williams W.J. et al., eds., Hematology, 4th ed. , 1990, McGraw-Hill Inc., pp. 1189 and 1382) .

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne un essai destiné au diagnostic de la schizophrénie chez un sujet. L'essai se déroule en plusieurs opérations: (a) prélèvement d'un échantillon de sang, ou séparation de la fraction thrombocytaire d'un échantillon de sang, ou encore séparation d'une fraction contenant des anticorps associés aux thrombocytes ou 'PAA' à partir d'un échantillon de sang prélevé chez un sujet; (b) mise en contact de l'échantillon, d'abord avec des antigènes thrombocytaires fixés sur un support solide, puis avec un système de détection d'anticorps; et (c) détermination des antigènes thrombocytaires du PAA et comparaison par rapport à la structure de liaison d'un échantillon prélevé chez un sujet témoin. Une différence structurelle est l'indice d'une forte probabilité de schizophrénie chez le sujet. L'essai permet de distinguer entre schizophrénie et démence, de même qu'entre thrombocythopénie chronique idiopathique et affections auto-immunes dirigées contre un antigène thrombocytaire.
PCT/US1995/002426 1994-03-01 1995-02-28 Essai destine au diagnostic de la schizophrenie WO1995023970A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP95912625A EP0748447A4 (fr) 1994-03-01 1995-02-28 Essai destine au diagnostic de la schizophrenie
JP7522960A JPH09510012A (ja) 1994-03-01 1995-02-28 精神分裂病の診断のためのアッセイ
BR9507125A BR9507125A (pt) 1994-03-01 1995-02-28 Teste e kit para o diagnóstico de esquizofrenia em um indivíduo
AU19716/95A AU695043B2 (en) 1994-03-01 1995-02-28 Assay for the diagnosis of schizophrenia

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL10878994A IL108789A (en) 1994-03-01 1994-03-01 Assay for diagnosis of schizophrenia
IL108789 1994-03-01
IL11014294A IL110142A0 (en) 1994-06-28 1994-06-28 Assay for diagnosis of schizophrenia
IL110142 1994-06-28

Publications (1)

Publication Number Publication Date
WO1995023970A1 true WO1995023970A1 (fr) 1995-09-08

Family

ID=26322789

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/002426 WO1995023970A1 (fr) 1994-03-01 1995-02-28 Essai destine au diagnostic de la schizophrenie

Country Status (6)

Country Link
EP (1) EP0748447A4 (fr)
JP (1) JPH09510012A (fr)
AU (1) AU695043B2 (fr)
BR (1) BR9507125A (fr)
CA (1) CA2184602A1 (fr)
WO (1) WO1995023970A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997013152A1 (fr) * 1995-09-29 1997-04-10 Yeda Research And Development Co., Ltd. Dosage permettant de diagnostiquer la demence
WO1999051725A3 (fr) * 1998-04-02 1999-12-02 Yeda Res & Dev Methode de diagnostic de la schizophrenie basee sur un peptide nouveau
RU2216741C1 (ru) * 2000-10-31 2003-11-20 Джапэн Эз Репрезентед Бай Президент Оф Ниигата Юниверсити Диагностический набор для выявления шизофрении
WO2002074793A3 (fr) * 2001-03-21 2004-02-26 Yeda Res & Dev Nouveaux peptides permettant le diagnostic de la schizophrenie

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL107515A (en) * 1993-11-05 1997-01-10 Yeda Res & Dev Diagnosis of mental disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANNALS NEW YORK ACADEMY OF SCIENCES, Volume 621, issued 01 July 1991, M. SHINITZKY et al., "Platelet Autoantibodies in Dementia and Schizophrenia - Possible Implications for Mental Disorders", pages 205-217. *
LANCET, Volume 344, No. 8914, issued 02 July 1994, J. LEVINE et al., "Treatment of Schizophrenia with an Immunosuppressant", pages 59-60. *
PSYCHOBIOLOGY, Volume 21, No. 4, issued April 1993, A. KESSLER et al., "Platelets from Schizophrenic Patients Bear Autoimmune Antibodies that Inhibit Dopamine Uptake", pages 299-306. *
See also references of EP0748447A4 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997013152A1 (fr) * 1995-09-29 1997-04-10 Yeda Research And Development Co., Ltd. Dosage permettant de diagnostiquer la demence
WO1999051725A3 (fr) * 1998-04-02 1999-12-02 Yeda Res & Dev Methode de diagnostic de la schizophrenie basee sur un peptide nouveau
US7098304B1 (en) 1998-04-02 2006-08-29 Yeda Research And Development Co. Ltd. Assay for the diagnosis of schizophrenia based on a new peptide
RU2216741C1 (ru) * 2000-10-31 2003-11-20 Джапэн Эз Репрезентед Бай Президент Оф Ниигата Юниверсити Диагностический набор для выявления шизофрении
WO2002074793A3 (fr) * 2001-03-21 2004-02-26 Yeda Res & Dev Nouveaux peptides permettant le diagnostic de la schizophrenie
US7354991B2 (en) 2001-03-21 2008-04-08 Yeda Research And Development Co. Ltd Peptides for the diagnosis of schizophrenia

Also Published As

Publication number Publication date
CA2184602A1 (fr) 1995-09-08
EP0748447A1 (fr) 1996-12-18
AU695043B2 (en) 1998-08-06
JPH09510012A (ja) 1997-10-07
BR9507125A (pt) 1997-09-30
AU1971695A (en) 1995-09-18
EP0748447A4 (fr) 1998-11-18

Similar Documents

Publication Publication Date Title
JP3202772B2 (ja) ヘリコバクターピロリ検出用の抗原調製物
US5506110A (en) Carrier for binding of anti-phospholipid antibodies, and immunoassay method using the same and a kit therefor
US7462495B2 (en) Methods and compositions for use in diagnosing and characterizing chronic immune disease
IE47031B1 (en) Carrier-bound immunoglobulin fission product and its use in immunologic analyses
EP0856158B1 (fr) Dosage permettant de diagnostiquer la demence
AU695043B2 (en) Assay for the diagnosis of schizophrenia
US6008001A (en) Diagnosis of the susceptibility of contracting schizophrenia
CA2175697C (fr) Diagnostic de maladies mentales
IL108789A (en) Assay for diagnosis of schizophrenia
JP2009508087A (ja) モノクローナル抗体試薬
CN117624350B (zh) 一种抗人磷酸化tau217兔单克隆抗体及其应用
JP3225248B2 (ja) 検出方法
AU2004258830A1 (en) Methods and compositions for use in diagnosing and characterizing diseases involving abnormal apoptosis
Rotmans et al. Separation and comparative immunoassay (DASS, ELISA) with antigens from adult Schistosoma mansoni
JP2595921B2 (ja) 抗ｒｎａ結合蛋白質抗体の測定法
AU2020200382A1 (en) Serological detection of Plasmodium antibodies
JPH06300764A (ja) 抗リン脂質抗体結合用担体、それを使用する免疫学的測定およびキット
WO1986006382A1 (fr) DETECTION D'ANTICORPS DE l'ENCEPHALOMYELITE AVIENNE
JP2001302697A (ja) ポリクローナル抗体及びその製造方法
JPH0822875B2 (ja) 精製されたｒｎａ結合蛋白質の製造法
JPS62503123A (ja) 免疫複合物の検定のための方法および物品

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2184602

Country of ref document: CA

Ref document number: 1995912625

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1996 702635

Country of ref document: US

Date of ref document: 19961106

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1995912625

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995912625

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载